Literature DB >> 31780842

Engaging patients in medicines regulation: a tale of two agencies.

Maria Mavris, Andrea Furia Helms, Nathalie Bere.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31780842     DOI： 10.1038/d41573-019-00164-y

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Patient-Centered Core Impact Sets: What They are and Why We Need Them.

Authors:  Eleanor M Perfetto; Elisabeth M Oehrlein; T Rosie Love; Silke Schoch; Annie Kennedy; Jennifer Bright
Journal:  Patient       Date:  2022-06-02       Impact factor: 3.481

Review 2.  Practices of patient engagement in drug development: a systematic scoping review.

Authors:  Olga Zvonareva; Constanța Craveț; Dawn P Richards
Journal:  Res Involv Engagem       Date:  2022-06-29

Review 3.  Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.

Authors:  Carla Epps; Ralph Bax; Alysha Croker; Dionna Green; Andrea Gropman; Agnes V Klein; Hannah Landry; Anne Pariser; Marc Rosenman; Michiyo Sakiyama; Junko Sato; Kuntal Sen; Monique Stone; Fumi Takeuchi; Jonathan M Davis
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

4.  Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes.

Authors:  Giampaolo Brichetto; Paola Zaratin
Journal:  Curr Opin Neurol       Date:  2020-06       Impact factor: 5.710

5.  Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.

Authors:  Maria Cavaller-Bellaubi; Stuart D Faulkner; Bryan Teixeira; Mathieu Boudes; Eva Molero; Nicholas Brooke; Laura McKeaveney; Jeffrey Southerton; Maria José Vicente; Neil Bertelsen; Juan García-Burgos; Vinciane Pirard; Kirsty Reid; Elisa Ferrer
Journal:  Ther Innov Regul Sci       Date:  2021-05-10       Impact factor: 1.778

Review 6.  Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.

Authors:  Olalekan Lee Aiyegbusi; Lavinia Ferrante di Ruffano; Ameeta Retzer; Philip N Newsome; Christopher D Buckley; Melanie J Calvert
Journal:  Trials       Date:  2022-01-15       Impact factor: 2.279

Review 7.  Translational precision medicine: an industry perspective.

Authors:  Dominik Hartl; Valeria de Luca; Anna Kostikova; Jason Laramie; Scott Kennedy; Enrico Ferrero; Richard Siegel; Martin Fink; Sohail Ahmed; John Millholland; Alexander Schuhmacher; Markus Hinder; Luca Piali; Adrian Roth
Journal:  J Transl Med       Date:  2021-06-05       Impact factor: 5.531

8.  Methodological Priorities for Patient Preferences Research: Stakeholder Input to the PREFER Public-Private Project.

Authors:  Ian P Smith; Rachael L DiSantostefano; Esther W de Bekker-Grob; Bennett Levitan; Conny Berlin; Jorien Veldwijk; G Ardine de Wit
Journal:  Patient       Date:  2021-03-15       Impact factor: 3.883
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.